Showing results (841-850 of 858) with videos related to

Sort By:
Pageof 86
BMC Cancer|November 7, 2025
Clinical features and prognostic factors of ovarian cancer brain metastases from ovarian cancer: a retrospective multicenter study of 129 casesYingying Wang, Qiyue Chao, Xiaoyan Lu, et al.
Journal of Gynecologic Oncology|August 19, 2020
Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial conceptRong Jiang, Jianqing Zhu, Jae Weon Kim, et al.
The Lancet Regional Health. Western Pacific|April 25, 2022
Transplantation of a beating heart: A first in manShengli Yin, Jian Rong, Yinghua Chen, et al.
Journal of Hepatology|March 4, 2024
CD1d protects against hepatocyte apoptosis in non-alcoholic steatohepatitisZhigang Lei, Jiaojiao Yu, Yu Wu, et al.
Plos One|June 27, 2024
Prediction of final pathology depending on preoperative myometrial invasion and grade assessment in low-risk endometrial cancer patients: A Korean Gynecologic Oncology Group ancillary studyDong-Hoon Jang, Hyun-Gyu Lee, Banghyun Lee, et al.
The New England Journal of Medicine|October 15, 2025
Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical CancerHua Tu, He Huang, Yanfang Li, et al.
Journal of Gynecologic Oncology|April 23, 2020
A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 studyTingyan Shi, Sheng Yin, Jianqing Zhu, et al.
Cancer|January 10, 2017
Preoperative assessment of lymph node metastasis in endometrial cancer: A Korean Gynecologic Oncology Group studySokbom Kang, Joo-Hyun Nam, Duk-Soo Bae, et al.
The Lancet. Oncology|December 4, 2023
Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trialKezhen Li, Jing Chen, Yingjie Hu, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
Pageof 86